Investigator

Madison Miller

Measurement Incorporated United States

MMMadison Miller
Papers(1)
Evaluation of toxicit…
Collaborators(3)
Claire F. FriedmanJulia ShufordKay Park
Institutions(3)
Measurement Incorpora…Memorial Sloan Ketter…Winship Cancer Instit…

Papers

Evaluation of toxicity after radical hysterectomy or trachelectomy and post-operative pelvic intensity-modulated radiation therapy with concurrent chemotherapy for cervical cancer

Compared to historical standards, intensity-modulated radiation therapy minimizes radiation dose to critical structures. Here, we characterize acute/chronic complications of intensity-modulated radiation therapy with concurrent chemotherapy following radical surgery for cervical cancer. This single-institution, retrospective study included patients who underwent radical hysterectomy/trachelectomy followed by adjuvant intensity-modulated radiation therapy and radiosensitizing chemotherapy for clinical stage IA to IIA cervical cancer (01/2007-8/2021). Treatment-related adverse events were collected and graded at baseline, 3 weeks, and 5 weeks after intensity-modulated radiation therapy, and long-term (≥6 months). We identified 91 patients who received intensity-modulated radiation therapy with concurrent chemotherapy following radical hysterectomy (n = 84, 92%) or radical trachelectomy (n = 7, 8%). Post-operatively, 66 patients (73%) met Peters criteria, 21 (23%) met Sedlis criteria, and 4 (4%) had other high-risk features. Intensity-modulated radiation therapy doses were 5040 cGy in 66% (n = 60) of patients, 4500 cGy in 30% (n = 27), and 4500 to 5040 cGy in 4% (n = 4). The most common treatment-related adverse events were fatigue (n = 77, 85%) and gastrointestinal (n = 74, 81%), followed by hematologic (n = 26, 29%) and genitourinary (n = 35, 38%). From baseline to intensity-modulated radiation therapy completion, adverse event scores significantly worsened for hematologic (p < .002), fatigue (p < .0001), gastrointestinal (p < .0001), and genitourinary toxicities (p = .003). Acute grade 3 toxicities occurred in 2% (n = 2, gastrointestinal and fatigue). There was one chronic grade 3 toxicity: lymphedema requiring lymphovenous bypass in a patient who underwent full pelvic lymphadenectomy. We observed no long-term grade 3 bowel toxicity or radiation-associated secondary malignancy. Radical hysterectomy/trachelectomy followed by intensity-modulated radiation therapy with concurrent chemotherapy was associated with acceptable rates of acute/chronic toxicity. With modern post-operative intensity-modulated radiation therapy techniques, multimodal therapy for apparent stage I cervical cancer is reasonable with a very low rate of severe chronic genitourinary or gastrointestinal toxicities. Providers should continue to offer radical surgery for appropriate candidates.

1Papers
3Collaborators